This is right DMX-200 works alongside the gold standard and not to replace it. A 10% reduction in proteinuria lowers end stage disease risk is deemed to be a clinical meaningful difference in eGFR slope. DMX Ph2 results DMX-200 produced a combined ~35% reduction in proteinuria where as current gold standard working alone achieved 18%. The combined medication is 94% (nearly double) better than when the gold standard is administered alone that is a huge improvement and no doubt ADVANZ medical experts and advisers (not randoms on the web who pretend to have more insight) were impressed enough to sign a deal.
- Forums
- ASX - By Stock
- DXB
- Ann: ACTION3 IND Approved in China
Ann: ACTION3 IND Approved in China, page-149
-
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.0¢ |
Change
-0.040(8.16%) |
Mkt cap ! $250.7M |
Open | High | Low | Value | Volume |
48.5¢ | 48.5¢ | 44.8¢ | $1.098M | 2.375M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 337999 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 17466 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 337999 | 0.450 |
4 | 121348 | 0.445 |
1 | 20000 | 0.440 |
1 | 2873 | 0.435 |
3 | 20734 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 88538 | 4 |
0.475 | 18000 | 2 |
0.480 | 44694 | 2 |
0.490 | 112222 | 3 |
0.495 | 111559 | 4 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |